Floatz logo

Irinotecan

Adult Lymphocyte Depletion Hodgkin Lymphoma

National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Adult Lymphocyte Depletion Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
Inno-206
Northwestern University
Phase 2BB
Vinorelbine
National Cancer Institute (NCI)
Phase 2B
DEXAMETHASONE
Ohio State University Comprehensive Cancer Center
Phase 2B
Bortezomib
National Cancer Institute (NCI)
Phase 2B
Bendamustine
Wake Forest University Health Sciences
Phase 1/2B

View all 21 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →